Tagada vs Remedora for Peptide & Telehealth Brands (2026)

Key takeaways

Tagada and Remedora are not competitors in the usual sense. Tagada is checkout, CRM and payment processing (TagadaPay). Remedora is an all-in-one telehealth platform: intake, prescribers, pharmacy and payments through third-party gateways.
The first question is your business model, not the vendor. A prescription-path peptide brand needs a clinical and pharmacy chain; a research-use supplier needs a merchant account that will underwrite it. Remedora does not serve the second group at all.
When we re-checked on 27 September 2026, TagadaPay’s site had been rewritten: the pages we could retrieve no longer named peptides as an onboarded industry or showed the reserve, payout and termination terms we documented on 23 September. Its new policy page says “a category we serve today may stop being one.”
Remedora’s Terms of Service and Privacy Policy pages still rendered no terms text on 27 September 2026, as on 23 September. Tagada Rx, Tagada’s telehealth layer, publishes 6.9% of GMV as a merchant-of-record fee.
Neither vendor is recommended or ranked here. Peptide Ad Lab has no relationship with either. The table of unverified items is the most useful part of this page.

What is the difference between Tagada and Remedora for a peptide company?

Tagada is a commerce and payments company: a checkout and subscription CRM plus its own processor, TagadaPay. Remedora is a telehealth platform that bundles patient intake, a licensed provider network, e-prescribing, pharmacy fulfilment and subscription billing through Stripe or NMI gateways. They overlap only for prescription-path brands, where Tagada Rx and Remedora both offer a clinical and pharmacy chain; for research-use peptide suppliers, Remedora is not an option at all.

We have published separate evidence-based profiles of Tagada and Remedora. This page puts them side by side because founders keep asking the question as a head-to-head, and the honest answer is that it usually is not one.

How this comparison was built

Every fact comes from the two vendors’ own public pages and documentation, read on 23 September 2026 and re-checked on 27 September 2026, unless labelled otherwise. Peptide Ad Lab has no affiliate, referral or commercial relationship with either company and has not used either platform. We do not rank vendors. Where something could not be verified, the table says so.

Which one fits your business model?

Start from how your products reach a customer. The vendor question follows from that.

Your model	What you actually need	Tagada	Remedora
Research-use supplier (no prescriber, no pharmacy)	A merchant account that will underwrite you, plus checkout	Possible fit for checkout; processor eligibility for peptides is now unclear (see re-check below)	Not a fit. Its own peptide article says a research-use disclaimer “is not a license”
Prescription-path brand building from scratch	Intake, licensed prescribers, pharmacy, subscriptions, LegitScript pathway	Tagada Rx: intake, clinician review, e-prescribing and partner pharmacy on a Tagada store	Core use case: storefront, providers, pharmacy and payments bundled
Prescription-path brand with its own clinical partners	Checkout, subscriptions, payment routing	Tagada CRM and TagadaPay, or Tagada Rx “Direct Merchant” mode (listed as coming soon)	Possible, but you would be paying for a bundled chain you may not use
Compounding pharmacy or clinic	Pharmacy systems, licensure, certification	Not its stated focus	Not its stated focus; it routes to partner pharmacies

If your products have no lawful prescription pathway, no telehealth platform changes that. Remedora’s own blog calls telehealth “a delivery mechanism for a lawful clinical process, not a laundering step.” Our compounded GLP-1 advertising guide covers what Google requires on the prescription side.

How do Tagada and Remedora compare on what they publish?

Item	Tagada	Remedora
Category	Checkout and CRM (Tagada CRM) plus payment processor (TagadaPay)	All-in-one telehealth platform
Contracting entity	TagadaPay LLC, Houston, Texas (Terms of Use, last updated 4 August 2025)	“Remedora Inc.” in the footer; about page states Florida headquarters
Is it a processor?	Yes (TagadaPay), and it can also route to other gateways	No; lists Stripe and NMI as gateways
Published price	Processing “from 2.9% + $0.29”; high-risk verticals “priced case by case”	Platform “starting $200 / month”; provider and pharmacy costs not published as a rate card
Telehealth pricing	Tagada Rx merchant-of-record mode: 6.9% of GMV, processing included, clinician and pharmacy costs at cost. Direct mode “coming soon” at 4.9% plus $4,980 setup	“Starting $200 / month,” described as one flat bill
Peptide stance	Named peptides as an onboarded industry on 23 September 2026; not found on the pages we retrieved on 27 September 2026	Peptides not a listed vertical; blog says research-use products cannot lawfully be sold for human use
LegitScript	Tagada Rx docs say merchant-of-record brands run on Tagada’s LegitScript infrastructure	Claims LegitScript Enterprise Certification Partner status; “more than 100” brands certified, typically 6–10 business days (its own observed range)
Legal pages	Terms of Use published with dates	Terms and Privacy pages rendered headings only, no terms text (23 and 27 September 2026)
Data portability	TagadaPay says cards, tokens and customer data are portable to other processors	Export terms not published

What changed on Tagada’s site between 23 and 27 September 2026?

On 23 September 2026, TagadaPay’s homepage listed “Peptides” among the ecommerce industries it onboards, with the condition that a call with an account manager was required before the dashboard was unlocked. It also published a typical 10% rolling reserve held 60–90 days, T+2 payouts in major markets, $25 dispute and $30 alert fees, and balances held up to 180 days after termination. Our Tagada profile documented all of this.

On 27 September 2026, the homepage had been rewritten. Its industry copy read “DTC, subscriptions, info products, supplements, SaaS, coaching, high-ticket,” with no mention of peptides or CBD, and the reserve and termination terms were no longer in the page source we retrieved. The application form’s ecommerce options listed DTC, subscriptions, supplements, beauty, apparel and high-ticket. A new “Prohibited conduct” page says business categories are “assessed case by case,” that “some categories require an additional conversation before an account is enabled,” and that “a category we serve today may stop being one.” Headline processing pricing (from 2.9% + $0.29) was unchanged.

What this does and does not mean

We cannot tell from public pages whether Tagada has stopped onboarding peptide merchants, moved that information elsewhere, or simply shortened its copy. The page does not say. What it shows is the general point: vendor web pages are not contracts, and a category listed one week can disappear the next. Ask compliance@tagada.io directly, and get category acceptance, reserve and termination terms in your merchant agreement.

What could we not verify for either vendor?

Question	Tagada	Remedora
Is peptide business currently accepted?	Could not verify after 27 September 2026 site change	Research-use: no, by its own content. Prescription peptides: no published formulary
Pricing for your category	Could not verify; high-risk priced case by case	Could not verify beyond $200/month starting price
Acquiring banks or merchant of record	Acquirers not named	Who holds the merchant account behind Stripe or NMI is not stated
Pharmacy partners	Tagada Rx partners not named on pages reviewed	Not named
LegitScript status	Not checked	Claimed; LegitScript’s checker is reCAPTCHA-gated and our lookup did not complete
Full contract terms	Terms of Use published; merchant agreement not public	Terms page empty when read
Server-side Google Ads conversions	Pricing lists server-side tracking; docs we read describe client-side Google tags	Google Ads listed as an integration; method not documented on pages reviewed
Independent customer experience	Not assessed for either. We did not survey users or rely on review sites.

How does either choice affect Google Ads and Merchant Center?

Neither vendor makes a product eligible to advertise. Google reviews the storefront and the product, not the checkout provider. Three practical points still apply:

Prescription brands need certification, whichever platform. Google requires LegitScript certification and then Google’s own healthcare certification for telemedicine and online pharmacy advertising. Remedora’s own LegitScript page says the application is filed in the brand’s own name. A storefront that is “live in hours” is not an ad account that is live in hours. See our LegitScript guide.
Tracking design matters more on telehealth funnels. Intake pages collect health information and Google offers no BAA for Google Ads. Ask either vendor which pages load advertising tags and what they send. Our HIPAA-conscious tracking guide lists the questions.
Payment stability affects Merchant Center. If a processor terminates you, checkout breaks, and Merchant Center reviews the checkout path. A sudden processor change is also a moment when price, availability and policy pages drift out of sync with the feed.

What should you get in writing before choosing either?

Category acceptance, in the agreement. Not a web page and not a sales call. Name your products.
Reserve, payout and termination terms. Percentage, holding period, triggers for change, and how long funds are held after the contract ends.
Merchant of record. Whose name appears on the cardholder statement and who carries chargeback liability.
Pharmacy and prescriber detail (prescription models). Named pharmacies, their 503A or 503B status and accreditation; who employs or contracts the prescribers.
Exit. Export of card tokens, subscriptions and patient or customer records, in what format and on what timeline.
Tracking. Exactly how conversions reach Google Ads and what data leaves the intake flow.

If you are weighing infrastructure changes alongside a Google Ads launch, the Readiness Score helps separate what is blocking you from what is merely untidy. To talk through your setup, book a strategy call.

Sources

TagadaPay — homepage (read 23 and 27 September 2026), Prohibited conduct, application form, Terms of Use
Tagada docs — Tagada Rx overview and operating modes
Remedora — Telehealth pricing, LegitScript certification, Are peptides legal? The 2026 rules
Remedora — Terms of Service and Privacy Policy (no terms text rendered, 23 and 27 September 2026)
Peptide Ad Lab — full vendor profiles: Tagada, Remedora

Checked 2026-09-27. Vendor pages change without notice; the signed agreement governs.

Founder Question

“Which one should we pick, Tagada or Remedora?”

Our Perspective

We do not recommend either and have no relationship with them. If you sell research-use peptides, Remedora is not built for you and Tagada’s current stance on the category is something to confirm in writing. If you are building a prescription brand, both offer a clinical and pharmacy chain — compare the contracts, pharmacy partners and exit terms, none of which either publishes in full.

Practical Recommendation

Decide your business model first. Research-use supply and prescription-path brands need different infrastructure, and Remedora serves only the second.
Treat vendor web pages as marketing, not terms. Tagada’s public peptide and reserve language changed within four days; get category acceptance and reserves in your agreement.
For prescription brands on either platform, plan LegitScript and Google certification separately from the platform launch.

What we learned

The most useful thing this comparison surfaced was not a feature difference. It was that one vendor’s public terms changed materially in four days, and the other’s legal pages have stayed empty. Operators often screenshot a vendor’s website as if it were a commitment. For high-risk categories in particular, the only terms that exist are the ones in your signed agreement.

Frequently asked

Is Tagada or Remedora better for a peptide company?

Neither is “better” in general; they are different categories. Tagada is checkout and payment processing. Remedora is a telehealth platform for prescription-led brands. Which one is relevant depends on whether your products have a prescription pathway.

Does Tagada still accept peptide merchants?

We cannot confirm it. TagadaPay named peptides as an onboarded industry on 23 September 2026, but the pages we retrieved on 27 September 2026 no longer did. Ask Tagada directly and get acceptance in your merchant agreement.

Can research peptide suppliers use Remedora?

No. Remedora is built for prescription-led brands, and its own peptide article says a research-use disclaimer is not a legal pathway for human use.

Do Tagada Rx and Remedora do the same thing?

They overlap. Both describe intake, clinician review, e-prescribing and partner pharmacy fulfilment. Tagada Rx publishes a 6.9% of GMV merchant-of-record fee; Remedora publishes a platform price starting at $200 a month. Neither publishes its pharmacy partners.

Does Peptide Ad Lab have a relationship with either vendor?

No. We have no affiliate, referral or commercial relationship with Tagada or Remedora, and this page does not rank or endorse either.

Next step

If you want this applied to your account and your site rather than read in the abstract, book a 30-minute strategy session. We will look at the domain before the call.

Book a Strategy Call

Tagada vs. Remedora for Peptide Companies: Different Categories, Compared on the Evidence